These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36879304)

  • 41. Exploring the experiences of clients receiving opioid use disorder treatment at a methadone clinic in Kenya: a qualitative study.
    Kiburi SK; Mwangi J; Maina G
    Addict Sci Clin Pract; 2022 Dec; 17(1):71. PubMed ID: 36510246
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gender disparities in access and retention in outpatient methadone treatment for opioid use disorder in low-income urban communities.
    Marsh JC; Amaro H; Kong Y; Khachikian T; Guerrero E
    J Subst Abuse Treat; 2021 Aug; 127():108399. PubMed ID: 34134873
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 44. Patient and provider perceptions of a peer-delivered intervention ('
    Rose AL; Belus JM; Hines AC; Barrie I; Regenauer KS; Andersen LS; Joska JA; Ciya N; Ndamase S; Myers B; Safren SA; Magidson JF
    Glob Ment Health (Camb); 2022; 9():439-447. PubMed ID: 36618732
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Medication for opioid use disorder treatment and specialty outpatient substance use treatment outcomes: Differences in retention and completion among opioid-related discharges in 2016.
    Askari MS; Martins SS; Mauro PM
    J Subst Abuse Treat; 2020 Jul; 114():108028. PubMed ID: 32527510
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of naltrexone in treating opioid use disorder in pregnancy.
    Towers CV; Katz E; Weitz B; Visconti K
    Am J Obstet Gynecol; 2020 Jan; 222(1):83.e1-83.e8. PubMed ID: 31376396
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Pilot Study of Training Peer Recovery Specialists in Behavioral Activation in the United States: Preliminary Outcomes and Predictors of Competence.
    Anvari MS; Kleinman MB; Dean D; Rose AL; Bradley VD; Hines AC; Abidogun TM; Felton JW; Magidson JF
    Int J Environ Res Public Health; 2023 Feb; 20(5):. PubMed ID: 36900912
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Depression and Outcomes of Methadone and Buprenorphine Treatment Among People with Opioid Use Disorders: A Literature Review.
    Ghabrash MF; Bahremand A; Veilleux M; Blais-Normandin G; Chicoine G; Sutra-Cole C; Kaur N; Ziegler D; Dubreucq S; Juteau LC; Lestage L; Jutras-Aswad D
    J Dual Diagn; 2020; 16(2):191-207. PubMed ID: 32089124
    [No Abstract]   [Full Text] [Related]  

  • 49. Risk factors for preterm birth among gravid individuals receiving buprenorphine for opioid use disorder.
    Abdelwahab M; Petrich M; Wang H; Walker E; Cleary EM; Rood KM
    Am J Obstet Gynecol MFM; 2022 May; 4(3):100582. PubMed ID: 35123110
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women.
    Tran TH; Griffin BL; Stone RH; Vest KM; Todd TJ
    Pharmacotherapy; 2017 Jul; 37(7):824-839. PubMed ID: 28543191
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
    Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
    Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: a National Drug Abuse Treatment Clinical Trials Network study.
    Peirce JM; Petry NM; Stitzer ML; Blaine J; Kellogg S; Satterfield F; Schwartz M; Krasnansky J; Pencer E; Silva-Vazquez L; Kirby KC; Royer-Malvestuto C; Roll JM; Cohen A; Copersino ML; Kolodner K; Li R
    Arch Gen Psychiatry; 2006 Feb; 63(2):201-8. PubMed ID: 16461864
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Does self-reported consumption of heroin correlate with dose of methadone among pregnant people with opioid use disorder?
    Gonzalez AM; Arlandson ME; Patel A; Premkumar A
    Am J Obstet Gynecol MFM; 2022 May; 4(3):100587. PubMed ID: 35123114
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Experiences of Clients in Three Types of Methadone Maintenance Therapy in an Atlantic Canadian City: A Qualitative Study.
    MacNeill L; Brunelle C; Skelding B; DiTommaso E
    Can J Nurs Res; 2021 Sep; 53(3):211-221. PubMed ID: 32414293
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Understanding concurrent stimulant use among people on methadone: A qualitative study.
    McNeil R; Puri N; Boyd J; Mayer S; Hayashi K; Small W
    Drug Alcohol Rev; 2020 Mar; 39(3):209-215. PubMed ID: 32202009
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Opioid Use Disorder Treatments: An Evidence Map.
    Sugarman A; Vittitow A; Cheng A; Malone M; McDonald R; Pace N; Williams O; Tofighi B; McNeely J; Schatz D; Roberts T; Hey SP; Garrity K; Lindquist K; Lee JD
    Drug Alcohol Depend; 2022 Dec; 241():109657. PubMed ID: 36332588
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    Bates AE; Martin-Misener R
    Can J Nurs Res; 2022 Mar; 54(1):15-26. PubMed ID: 33615847
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tailoring a brief intervention for illicit drug use and alcohol use in Irish methadone maintained opiate dependent patients: a qualitative process.
    Darker C; Sweeney B; Keenan E; Whiston L; Anderson R; Barry J
    BMC Psychiatry; 2016 Nov; 16(1):373. PubMed ID: 27809831
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Syringe service program-based telemedicine linkage to opioid use disorder treatment: protocol for the STAMINA randomized control trial.
    Watson DP; Swartz JA; Robison-Taylor L; Mackesy-Amiti ME; Erwin K; Gastala N; Jimenez AD; Staton MD; Messmer S
    BMC Public Health; 2021 Mar; 21(1):630. PubMed ID: 33789642
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Peer Activate: A Feasibility Trial of a Peer-Delivered Intervention to Decrease Disparities in Substance Use, Depression, and Linkage to Substance Use Treatment.
    Felton JW; Kleinman MB; Doran K; Satinsky EN; Tralka H; Dean D; Brown CJS; Anvari MS; Bradley VD; Magidson JF
    J Psychosoc Nurs Ment Health Serv; 2023 Nov; 61(11):23-31. PubMed ID: 37256749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.